
    
      The study subjects must have acne vulgaris and will apply study drug to their face for 12
      weeks.

      Study visits will occur at baseline (day 1) and at weeks 2, 4, 8, and 12. Subjects will be
      assessed at every visit to determine how the study drug is working. Safety will be assessed
      by evaluation of adverse events (AEs), vital signs, physical examinations, and withdrawals
      from the study.
    
  